Land Rover of Milford sponsors Rose of Hope Luncheon

Land Rover Milford will be the lead corporate sponsor of the Rose of Hope Celebrity Champagne Reception, part of the Rose of Hope Luncheon, an annual benefit for the Norma F. Pfriem Breast Care Center, for the second year.

The luncheon, which takes place in June, raises funds for the center’s programs for underserved women.

Each year the Breast Care Center helps more than 1,000 women access free screening and diagnostic services to prevent early death from breast cancer through its Medically Underserved Initiative, the largest program of free care in the area. The annual luncheon, which raises funds to support this program, attracts over 600 individuals, many of them breast cancer survivors, and takes place in Fairfield.

Television personalities Giuliana and Bill Rancic will deliver the keynote address. Giuliana, a breast cancer survivor, is the co-anchor of television’s E! News. Her husband, Bill, is a motivational speaker and Chicago real estate developer who was hired by The Trump Organization at the conclusion of the first season of The Apprentice.

“We are fortunate to have so many committed supporters and friends,” said Dr. Donna Twist, executive director of the Norma F. Pfriem Breast Care Center. “Land Rover’s generosity ensures that we can continue to make a difference in the lives of women and their families.”

For more information about sponsorship or for tickets to the Rose of Hope Luncheon, call the Breast Care Center at 203-255-5300.

Part of Bridgeport Hospital and the Yale New Haven Health System, the Norma F. Pfriem Breast Care Center has served more than 20,000 women and their families since it was established in 1999.

One of only 200 sites accredited by the National Accreditation Program for Breast Centers (NAPBC), the center provides a range of diagnostic care and treatment at its Bridgeport Hospital and Fairfield locations, including medical oncology, surgical and chemotherapy services, plastic surgery, mammography and radiation therapy, and genetic risk assessment as well as opportunities to participate in clinical trials.